Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

AbbVie (NY:ABBV)

184.03 -1.68 (-0.90%)
Streaming Delayed Price Updated: 2:42 PM EDT, May 20, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,542,036
Open 184.86
Bid (Size) 184.00 (1)
Ask (Size) 184.06 (1)
Prev. Close 185.71
Today's Range 183.63 - 186.00
52wk Range 153.58 - 218.66
Shares Outstanding N/A
Dividend Yield 3.56%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Don't Fall for These 3 Dividend Stocks: They May Have to Make a Cut.
Here are three dividend-paying stocks that warrant closer examination. 
Via The Motley Fool
Exposures COVID-19

Performance

YTD
+2.6%
+2.6%
1 Month
+8.2%
+8.2%
3 Month
-6.2%
-6.2%
6 Month
+10.7%
+10.7%
1 Year
+11.8%
+11.8%

More News

Read More
3 Magnificent Stocks That Are Passive Income Machines
Via The Motley Fool
3 Stocks That Will Profit From Trump's Drug Price Cut
Via Benzinga
Topics Government
Exposures Political
A Look Into AbbVie Inc's Price Over Earnings
Via Benzinga
What Does the Market Think About AbbVie?
Via Benzinga
AbbVie Unusual Options Activity
Via Benzinga
1 Healthcare Stock to Keep an Eye On and 2 to Ignore
Via StockStory
Topics Economy Stocks
Exposures COVID-19 Supply Chain US Equities
Why Pfizer Is Poised For A Strong Comeback: My Top Pick For 2025
Via Benzinga
Jim Cramer Says Even 'Safety' Stocks Look Risky, Warns Of 'Wild Card' In Washington And Rising Treasury Yields As Reasons To Stay Away From Sure Bets
Via Benzinga
Topics Bonds
Exposures Debt Markets
Stay informed with the top movers within the S&P500 index on Wednesday.
Via Chartmill
FDA Fast-Tracks AbbVie's New Lung Cancer Therapy Emrelis For Tough Lung Cancer Cases
Via Benzinga
Exposures Product Safety
AbbVie Gets FDA Nod For Drug To Treat Lung Cancer: Retail’s Yet To React
Via Stocktwits
Exposures Product Safety
What's going on in today's session: S&P500 movers
Via Chartmill
Expert Outlook: AbbVie Through The Eyes Of 10 Analysts
Via Benzinga
Q1 Therapeutics Earnings: United Therapeutics (NASDAQ:UTHR) Impresses
Via StockStory
Topics Artificial Intelligence
Exposures Artificial Intelligence
Congressional Trading Report: Rep. Jared Moskowitz Bought Over $27K In AbbVie Stock
Via Benzinga
Top S&P500 movers in Monday's pre-market session
Via Chartmill
S&P 500, Dow Jones Pharma Stocks Boomerang As Trump Threatens Drug-Price Reform
Via Investor's Business Daily
Topics Government Stocks
Exposures Political US Equities
Wall Street Rips Higher As Tariff Truce Halts US–China Economic Escalation
Via Benzinga
Topics Economy World Trade
Exposures Interest Rates Tariff
Recession Worries? Here's 1 of the Best Dividend Stocks for Turbulent Times
Via The Motley Fool
Topics Economy World Trade
Exposures Economy Tariff
2 High-Yield Dividend Stocks to Buy in May and Hold Forever
Via The Motley Fool
Topics Intellectual Property
Exposures Intellectual Property
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Recent Report Shows That Rep. Jefferson Shreve Bought Up to $4.75M Worth of Apple Stock
Via Benzinga
Thursday's session: gap up and gap down stock in the S&P500 index
Via Chartmill

Frequently Asked Questions

Is AbbVie publicly traded?
Yes, AbbVie is publicly traded.
What exchange does AbbVie trade on?
AbbVie trades on the New York Stock Exchange
What is the ticker symbol for AbbVie?
The ticker symbol for AbbVie is ABBV on the New York Stock Exchange
What is the current price of AbbVie?
The current price of AbbVie is 184.03
When was AbbVie last traded?
The last trade of AbbVie was at 05/20/25 02:42 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.